A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This trial is a single-center, single-dose, double-blind, parallel-group, randomized, 3-arm
PK trial in healthy male volunteers comparing a biosimilar pertuzumab (EG1206A) to a single
intravenous (i.v.) infusion to both European Union (EU) and United States of America (US)
reference products.